Characteristics of FLT3-ITD+ AML patients
| Diagnosis according to FAB . | Age (y) . | Karyotype . | Mutations . | Intermediate risk category* . |
|---|---|---|---|---|
| AML M4 | 52 | 46,XX,-8,+mar[2]/46,XX[28] | FLT3-ITD | II |
| AML M4 | 64 | 46,XY | FLT3-ITD | I |
| AML M2 | 75 | 46,XX | FLT3-ITD NPM1mut | I |
| AML M1 | 78 | 46,XY | FLT3-ITD | I |
| AML M1 | 68 | NT | FLT3-ITD NPM1mut | I |
| AML M4 relapse | 25 | 46,XY | FLT3-ITD | I |
| Diagnosis according to FAB . | Age (y) . | Karyotype . | Mutations . | Intermediate risk category* . |
|---|---|---|---|---|
| AML M4 | 52 | 46,XX,-8,+mar[2]/46,XX[28] | FLT3-ITD | II |
| AML M4 | 64 | 46,XY | FLT3-ITD | I |
| AML M2 | 75 | 46,XX | FLT3-ITD NPM1mut | I |
| AML M1 | 78 | 46,XY | FLT3-ITD | I |
| AML M1 | 68 | NT | FLT3-ITD NPM1mut | I |
| AML M4 relapse | 25 | 46,XY | FLT3-ITD | I |
FAB, French-American-British classification; M1, acute myeloblastic leukemia, without maturation; M2, acute myeloblastic leukemia, with granulocytic maturation; M4, acute myelomonocytic leukemia; NT, not tested.
According to the European LeukemiaNet classification.11